Internal Medicine, Rheumatology · Loxahatchee, FL
NPI
1932262516
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
12977 Southern Blvd Bldg 5, Suite 200
Loxahatchee, FL, 33470
Phone (561) 798-8184
Groups this clinician bills Medicare through
Medicare paid, 2024
$907K
52,533 services
Medicare patients, 2024
581
Average age 73
Drug cost, 2024
$7.0M
1,294 prescriptions
Company payments, 2025
$48K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Howard M Busch was code J3262 (injection, tocilizumab, 1 mg), 18,280 times for 13 patients. In total Howard M Busch billed 52,533 services in 77 codes, and Medicare paid $907K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 18,280 | 13 | $4.60 | $84K |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 10,800 | 12 | $3.03 | $33K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 4,600 | 23 | $29.68 | $137K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 3,990 | 11 | $8.75 | $35K |
| J0897 Injection, denosumab, 1 mg | Office | 660 | 11 | $21.31 | $14K |
| 99214 Office E&M - Established | Office | 632 | 371 | $98.17 | $62K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 489 | 52 | $0.11 | $51.72 |
| 73562 X-ray - Lower Extremity | Office | 269 | 137 | $33.97 | $9,138 |
| 96413 Chemotherapy Administration | Office | 194 | 79 | $108.11 | $21K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 186 | 159 | $13.47 | $2,506 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 152 | 12 | $0.23 | $35.56 |
| 72110 X-ray - Spine and Pelvis | Office | 139 | 138 | $39.41 | $5,478 |
| 72170 X-ray - Spine and Pelvis | Office | 130 | 129 | $21.16 | $2,751 |
| 73110 X-ray - Upper Extremity | Office | 108 | 59 | $31.56 | $3,409 |
| 72070 X-ray - Spine and Pelvis | Office | 104 | 104 | $25.89 | $2,693 |
By year: 2022 $1.1M for 72,611 services; 2023 $776K for 47,863 services; 2024 $907K for 52,533 services.
Medicare prescription drug claims, 2024
In 2024, the drug Howard M Busch prescribed most often to Medicare patients was Gabapentin, with 132 prescriptions and refills. In total Howard M Busch wrote 1,294 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 132 | 154 | 82 | $907 |
| Methylprednisolone Generic | 92 | 103 | 64 | $1,776 |
| Actemra Tocilizumab | 85 | 85 | Under 11 | $183K |
| Benlysta Belimumab | 81 | 81 | Under 11 | $254K |
| Orencia Abatacept/Maltose | 79 | 80 | 13 | $387K |
| Pregabalin Generic | 47 | 81 | 25 | $1,659 |
| Clonazepam Generic | 42 | 50 | 13 | $335 |
| Methotrexate Methotrexate Sodium | 42 | 77 | 20 | $516 |
| Celecoxib Generic | 40 | 55 | 28 | $635 |
| Tramadol Hcl Generic | 37 | 43 | 18 | $305 |
| Hydroxychloroquine Sulfate Generic | 36 | 67 | 19 | $787 |
| Prednisone Generic | 34 | 50 | 22 | $229 |
| Zoledronic Acid Zoledronic Acid/Mannitol-Water | 32 | 366 | 32 | $5,533 |
| Mycophenolate Mofetil Generic | 31 | 40 | Under 11 | $3,076 |
| Acthar Corticotropin | 31 | 37 | Under 11 | $4.7M |
Brand drugs: - claims; generic drugs: 793 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Howard M Busch $48K ($48K in general payments such as food, travel and fees) from 25 companies. The largest payer was Mallinckrodt Hospital Products Inc. with $16K.
| Company | Payments | Amount |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 18 | $16K |
| ANI Pharmaceuticals, Inc. ANIP | 27 | $7,987 |
| Amgen Inc. AMGN | 21 | $7,578 |
| AstraZeneca Pharmaceuticals LP AZN | 24 | $6,114 |
| GlaxoSmithKline, LLC. GSK | 10 | $5,455 |
| UCB, Inc. UCB.BR | 26 | $2,644 |
| Sobi, Inc SOBI.ST | 4 | $464 |
| Abbvie Inc. ABBV | 15 | $275 |
| Genzyme Corporation SNY | 6 | $246 |
| Pfizer Inc. PFE | 19 | $236 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.